To develop a paper-based diagnostic device for the rapid detection of miRNA-21, a microRNA associated with cancer.
Approach:
Key Findings:
The device demonstrated a detection range of 1–2000 nmol/L and a detection limit of 0.25 nmol/L under optimized laboratory conditions.
Successful detection of miRNA-21 was achieved in spiked human serum samples.
Interpretation:
The study indicates potential for paper-based microfluidic systems to facilitate faster and lower-cost cancer biomarker testing, particularly in resource-limited settings.
Limitations:
The assay is still experimental and requires substantial clinical validation before routine use.
Conclusion:
The research reflects ongoing efforts to enhance accessibility and scalability of molecular biomarker testing in clinical environments.
